DDInter1305 DDInter669
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Nitroprusside {u} (Compound) binds {v} (Gene) GUCY1A2
GUCY1A2 {u} (Gene) is bound by {v} (Compound) Nitroglycerin
Nitroglycerin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Nitroprusside {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Nitroprusside (Compound) binds GUCY1A2 (Gene) and GUCY1A2 (Gene) is bound by Nitroglycerin (Compound) and Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Nitroprusside (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin